Kazia Therapeutics Ltd ADR (KZIA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kazia Therapeutics Ltd ADR (KZIA) has a cash flow conversion efficiency ratio of 0.499x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.14 Million) by net assets ($-8.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kazia Therapeutics Ltd ADR market capitalisation for the company's overall valuation and market capitalisation.
Kazia Therapeutics Ltd ADR - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Kazia Therapeutics Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kazia Therapeutics Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kazia Therapeutics Ltd ADR ranked by their cash flow conversion efficiency. Explore KZIA cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
-0.141x |
|
ISU Abxis Co. Ltd
KQ:086890
|
0.088x |
|
Erbud SA
WAR:ERB
|
-0.262x |
|
NEW ZEALAND RURAL
F:8UK
|
N/A |
|
Gedeon Richter PLC
LSE:0QFP
|
0.038x |
|
Rent the Runway Inc
NASDAQ:RENT
|
0.071x |
|
Bumech S.A.
WAR:BMC
|
0.034x |
|
Salazar Resources Limited
V:SRL
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Kazia Therapeutics Ltd ADR (1999–2025)
The table below shows the annual cash flow conversion efficiency of Kazia Therapeutics Ltd ADR from 1999 to 2025. View Kazia Therapeutics Ltd ADR (KZIA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-8.30 Million | $-13.28 Million | 1.600x | +67.24% |
| 2024-06-30 | $-10.02 Million | $-9.58 Million | 0.956x | +176.05% |
| 2023-06-30 | $12.05 Million | $-15.16 Million | -1.258x | -0.98% |
| 2022-06-30 | $18.27 Million | $-22.76 Million | -1.246x | -417.44% |
| 2021-06-30 | $37.85 Million | $-9.11 Million | -0.241x | +61.41% |
| 2020-06-30 | $14.12 Million | $-8.81 Million | -0.624x | -31.63% |
| 2019-06-30 | $14.17 Million | $-6.71 Million | -0.474x | -5.27% |
| 2018-06-30 | $19.24 Million | $-8.66 Million | -0.450x | +0.26% |
| 2017-06-30 | $25.34 Million | $-11.43 Million | -0.451x | -27.82% |
| 2016-06-30 | $33.93 Million | $-11.98 Million | -0.353x | -171.96% |
| 2015-06-30 | $44.36 Million | $-5.76 Million | -0.130x | +96.79% |
| 2014-06-30 | $1.41 Million | $-5.71 Million | -4.043x | -135.09% |
| 2013-06-30 | $5.11 Million | $-8.79 Million | -1.720x | -19.66% |
| 2012-06-30 | $5.11 Million | $-7.35 Million | -1.437x | +27.00% |
| 2011-06-30 | $4.42 Million | $-8.70 Million | -1.969x | -56.23% |
| 2010-06-30 | $13.18 Million | $-16.61 Million | -1.260x | -76.02% |
| 2009-06-30 | $28.77 Million | $-20.60 Million | -0.716x | -26.89% |
| 2008-06-30 | $35.62 Million | $-20.10 Million | -0.564x | -72.36% |
| 2007-06-30 | $44.68 Million | $-14.63 Million | -0.327x | -1.07% |
| 2006-06-30 | $44.59 Million | $-14.44 Million | -0.324x | -52.98% |
| 2005-06-30 | $60.25 Million | $-12.76 Million | -0.212x | +3.34% |
| 2004-06-30 | $47.82 Million | $-10.48 Million | -0.219x | -58.72% |
| 2003-06-30 | $42.24 Million | $-5.83 Million | -0.138x | -11.68% |
| 2002-06-30 | $54.07 Million | $-6.68 Million | -0.124x | +63.23% |
| 2001-06-30 | $101.72 Million | $-34.18 Million | -0.336x | +5.51% |
| 2000-06-30 | $52.73 Million | $-18.75 Million | -0.356x | +19.47% |
| 1999-06-30 | $47.49 Million | $-20.97 Million | -0.442x | -- |
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase I… Read more